Topics:
Radiation Oncology • Thoracic Malignancies • General Radiation Oncology • Liver and Pancreas Tumors • Pulmonology
Can patients with alpha-1 antitrypsin deficiency have increased toxicity from radiation treatment to the lungs, liver or other areas?
Are there any documented/published toxicity concerns for treating lung, liver, or other targets (standard or hypofractionated) in a patient diagnosed with alpha-1 antitrypsin deficiency?